CD20 expression
|
NHL
|
CD20 expression
|
NHL
|
rituximab-arrx Sensitive: A1 - Approval
|
rituximab-arrx Sensitive: A1 - Approval
|
CD20 expression
|
CLL
|
CD20 expression
|
CLL
|
rituximab-arrx Sensitive: A1 - Approval
|
rituximab-arrx Sensitive: A1 - Approval
|
CD20 expression
|
B Acute Lymphoblastic Leukemia
|
CD20 expression
|
B Acute Lymphoblastic Leukemia
|
rituximab Sensitive: C2 – Inclusion Criteria
|
rituximab Sensitive: C2 – Inclusion Criteria
|
CD20 expression
|
Childhood B Acute Lymphoblastic Leukemia
|
CD20 expression
|
Childhood B Acute Lymphoblastic Leukemia
|
rituximab + bortezomib Sensitive: C3 – Early Trials
|
rituximab + bortezomib Sensitive: C3 – Early Trials
|
CD20 expression
|
NHL
|
CD20 expression
|
NHL
|
REGN1979 Resistant: C3 – Early Trials
|
REGN1979 Resistant: C3 – Early Trials
|
CD20 expression
|
Lymphoma
|
CD20 expression
|
Lymphoma
|
daratumumab + NKTR-255 Sensitive: C3 – Early Trials
|
daratumumab + NKTR-255 Sensitive: C3 – Early Trials
|
CD20 expression
|
Lymphoma
|
CD20 expression
|
Lymphoma
|
NKTR-255 + Ritucad (rituximab biosimilar) Sensitive: D – Preclinical
|
NKTR-255 + Ritucad (rituximab biosimilar) Sensitive: D – Preclinical
|
CD20 expression
|
NHL
|
CD20 expression
|
NHL
|
lenalidomide + GEN3013 Sensitive: D – Preclinical
|
lenalidomide + GEN3013 Sensitive: D – Preclinical
|